Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
GlaxoSmithKline ( (GB:GSK) ) has shared an update.
GSK disclosed that Chief People Officer Diana Conrad acquired 11.569 American Depositary Shares in the company at a price of $58.6439 per ADS through the GSK pension plan on 2 March 2026. The transaction, conducted on the New York Stock Exchange, reflects routine personal investment activity by a senior executive and is unlikely to materially affect GSK’s overall operations but provides additional transparency to shareholders regarding insider dealings.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £19.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
Spark’s Take on GB:GSK Stock
According to Spark, TipRanks’ AI Analyst, GB:GSK is a Neutral.
The score is driven primarily by strong profitability and improving recent fundamentals, supported by constructive 2026 guidance and pipeline momentum. Valuation is reasonable with a modest yield, while the main constraint is technical overbought risk and ongoing balance-sheet/earnings-consistency considerations.
To see Spark’s full report on GB:GSK stock, click here.
More about GlaxoSmithKline
GSK is a global biopharmaceutical company focused on uniting science, technology and talent to develop medicines and vaccines that help people get ahead of disease. The company operates internationally with a diversified portfolio across key therapeutic areas and maintains listings for its ordinary shares and American Depositary Shares in major markets.
Average Trading Volume: 8,962,046
Technical Sentiment Signal: Buy
Current Market Cap: £85.07B
Learn more about GSK stock on TipRanks’ Stock Analysis page.